Lantern Pharma Inc (LTRN) - Net Assets
Based on the latest financial reports, Lantern Pharma Inc (LTRN) has net assets worth $-3.22 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.60 Million) and total liabilities ($11.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Lantern Pharma Inc to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.22 Million |
| % of Total Assets | -37.4% |
| Annual Growth Rate | N/A |
| 5-Year Change | -90.87% |
| 10-Year Change | N/A |
| Growth Volatility | 742.31 |
Lantern Pharma Inc - Net Assets Trend (2018–2025)
This chart illustrates how Lantern Pharma Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Lantern Pharma Inc market cap and net worth.
Annual Net Assets for Lantern Pharma Inc (2018–2025)
The table below shows the annual net assets of Lantern Pharma Inc from 2018 to 2025. Also explore how fast is Lantern Pharma Inc growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.53 Million | -69.16% |
| 2024-12-31 | $21.19 Million | -48.21% |
| 2023-12-31 | $40.91 Million | -27.00% |
| 2022-12-31 | $56.04 Million | -21.70% |
| 2021-12-31 | $71.57 Million | +263.33% |
| 2020-12-31 | $19.70 Million | +1988.32% |
| 2019-12-31 | $943.28K | +567.44% |
| 2018-12-31 | $-201.80K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lantern Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8882153500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.12K | 0.02% |
| Other Comprehensive Income | $25.43K | 0.39% |
| Other Components | $99.65 Million | 1525.09% |
| Total Equity | $6.53 Million | 100.00% |
Lantern Pharma Inc Competitors by Market Cap
The table below lists competitors of Lantern Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hydrogen Refueling Solutions
PA:ALHRS
|
$21.86 Million |
|
Invoicery Group AB
ST:FRILAN
|
$21.88 Million |
|
M VEST WATER NK-00227652
F:7YA
|
$21.88 Million |
|
HUTCHMED China Ltd
LSE:HCM
|
$21.89 Million |
|
NV Gold Corp
V:NVX
|
$21.85 Million |
|
Daesung Eltec Co. Ltd
KQ:025440
|
$21.85 Million |
|
Kidoz Inc
V:KIDZ
|
$21.85 Million |
|
Yayla Enerji Uretim Turizm ve
IS:YAYLA
|
$21.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lantern Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,187,774 to 6,534,224, a change of -14,653,550 (-69.2%).
- Net loss of 17,119,438 reduced equity.
- New share issuances of 1,624,547 increased equity.
- Other comprehensive income decreased equity by 128,560.
- Other factors increased equity by 969,901.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.12 Million | -262.0% |
| Share Issuances | $1.62 Million | +24.86% |
| Other Comprehensive Income | $-128.56K | -1.97% |
| Other Changes | $969.90K | +14.84% |
| Total Change | $- | -69.16% |
Book Value vs Market Value Analysis
This analysis compares Lantern Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.03 | $1.71 | x |
| 2019-12-31 | $0.15 | $1.71 | x |
| 2020-12-31 | $3.17 | $1.71 | x |
| 2021-12-31 | $6.56 | $1.71 | x |
| 2022-12-31 | $5.16 | $1.71 | x |
| 2023-12-31 | $3.77 | $1.71 | x |
| 2024-12-31 | $1.97 | $1.71 | x |
| 2025-12-31 | $0.60 | $1.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lantern Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -262.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.69x
- Recent ROE (-262.00%) is above the historical average (-3268.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.71 Million |
| 2019 | -257.42% | 0.00% | 0.00x | 1.52x | $-2.52 Million |
| 2020 | -29.99% | 0.00% | 0.00x | 1.03x | $-7.88 Million |
| 2021 | -17.27% | 0.00% | 0.00x | 1.03x | $-19.52 Million |
| 2022 | -25446.91% | 0.00% | 0.00x | 1.05x | $-14.27 Billion |
| 2023 | -39.02% | 0.00% | 0.00x | 1.07x | $-20.05 Million |
| 2024 | -98.08% | 0.00% | 0.00x | 1.21x | $-22.90 Million |
| 2025 | -262.00% | 0.00% | 0.00x | 1.69x | $-17.77 Million |
Industry Comparison
This section compares Lantern Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lantern Pharma Inc (LTRN) | $-3.22 Million | 0.00% | N/A | $21.86 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor,… Read more